Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 120 participants.

Also called NCT02675790

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02675790
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Nigeria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02675790. Randomized; quadruple masking; primary purpose prevention. Start 2017-01 (actual); primary completion 2020-03-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
Acronym
SPRINT
Condition
Sickle Cell Disease
Condition
Sickle Cell Anemia
Condition
Stroke
Intervention (Drug)
Moderate Dose Hydroxyurea
Intervention (Drug)
Low Dose Hydroxyurea
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
Aminu Kano Teaching Hospital (class: other)
Collaborator
Murtala Muhammed Specialist Hospital (class: other)

Record details

Record id
cardio:ct-nct02675790
Content hash
a6a2f50bb4baa9f434c14e1bccb94641c935f71a1fd15c1e7c8d1b724fca7722